By inhibiting STAT3 phosphorylation, AG-490 is effective in reducing osteolysis and tumor growth of metastatic breast cancer, suggesting the potential of STAT3 as a therapeutic target in treating breast cancer bone metastases. Here, STAT3 is linked to breast cancer.